Two years af­ter a wrench­ing set­back, Pro­tag­o­nist touts a slice of da­ta and sets sights on piv­otal tri­al in a sur­pris­ing place: the blood

In 2018, the floor fell out be­neath Pro­tag­o­nist Ther­a­peu­tics. Months ahead of an ex­pect­ed read­out, the com­pa­ny’s first ma­jor tri­al, a Phase IIb test­ing their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER